Outcome of Board Meeting inter-alia to consider and approve the Standalone and Consolidated quarter and year ended March 31, 2025 financial results
BNAGROCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board, at its meeting on June 14, 2025, approved the audited consolidated and standalone financial results for Q4 and FY ended March 31, 2025, along with an unmodified auditor's opinion from M/s JSMG & Associates. On a consolidated basis, revenue from operations surged to Rs 29,940.64 lakhs (from Rs 708.80 lakhs in FY24), and the company swung to a net profit of Rs 1,975.56 lakhs versus a loss of Rs 312.50 lakhs in FY24, with basic EPS of Rs 9.35. Standalone revenue grew to Rs 2,562.89 lakhs, but the standalone loss widened sharply to Rs 5,963.13 lakhs (from Rs 312.62 lakhs), with basic EPS of Rs -28.23. Consolidated operating cash flow was negative at Rs -3,127.01 lakhs and standalone operating cash flow was also negative at Rs -317.59 lakhs. Total consolidated assets expanded to Rs 66,205.47 lakhs, largely driven by Rs 28,866.33 lakhs in trade receivables and Rs 29,012.09 lakhs in other non-current assets.
Group-level numbers show a dramatic turnaround and massive revenue expansion, likely from newly consolidated subsidiaries (BN Holdings Europe, Singapore, and Liberia operations). However, the standalone business remains loss-making and is bleeding more than before, while both standalone and consolidated operating cash flows are negative — meaning reported profits are not yet translating into cash, a key concern for shareholders.